FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
about
Atypical hemolytic uremic syndromeADAMTS13 substrate recognition of von Willebrand factor A2 domainMultiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural OverviewADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpuraInflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cellsIncreased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivoAllosteric activation of ADAMTS13 by von Willebrand factor.Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome.A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry.Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate.Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.A rapid enzyme-linked assay for ADAMTS-13.ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.A new tool to further explore the role of ADAMTS-13 in health and disease.ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpuraNormal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development.Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiencyDegradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapyA novel association of acquired ADAMTS13 inhibitor and acute dengue virus infectionAn autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWFA 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceA difficult diagnosis case of prolonged thrombocytopenia with sepsis and disseminated intravascular coagulation.Escherichia coli-derived von Willebrand factor-A2 domain fluorescence/Förster resonance energy transfer proteins that quantify ADAMTS13 activity.Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpuraRecombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in JapanHumoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome
P2860
Q21202864-0A502B4B-8DD5-4583-91CE-6F2595F36FEAQ24338203-FBC4E5AA-271B-46F0-9FDC-E6601A6562FCQ24620546-4628A794-050D-4E50-92DC-A7DD3694AFFDQ26747656-51B39917-14B9-4118-BAD2-EC5F98790F57Q28083264-4CCF7CA5-B303-4E52-9784-7F6544A69A53Q28564426-DD6D56C7-A8C1-4180-B4BC-E2F8E5D4B647Q28584350-6B1FAFB8-F800-4EEA-8672-E0B18E881628Q29568910-72F52FAA-02CF-4A5D-86BD-406708FBCDF7Q30364288-9A03AB57-F8C8-4745-B584-252DB63C725DQ30543370-439AD4BC-3A47-41ED-9117-58CEEFF1774AQ33231922-CC64A25A-7BE3-404F-B803-421E721B29C6Q33303263-2C12FC26-6281-475D-9203-0D8FC690A4EAQ33327295-33D531E7-07C1-4B79-A331-30FECDAAB62EQ33369765-A2F20FD0-961E-4651-8493-F8E345617D3BQ33369893-DDFD8034-7F0C-4C9A-BC4D-EEA3696EAE1EQ33371103-54FD3B61-493B-4E97-95E5-732D2D7C55BFQ33371176-41F21555-B0F2-4240-8AA6-22483D9B05ACQ33371177-BBEEFBF8-3F4F-4557-89A8-4DE3D1B66826Q33372115-B3EE9769-B096-4031-B532-3ADB9D94E5BFQ33373698-61938D32-2EFD-4745-A3B1-0A46AFF56A01Q33374478-10BD088F-AAC1-4C05-87B3-BFFA8EE2C76CQ33376071-213395A2-5B4D-40AC-8BA5-3AE27D8889C9Q33378594-55AB5820-F9A0-46A1-BCFB-3B0B2D6936DEQ33380771-D1BA4594-FEC4-465D-A2C1-5EBA01B94CAAQ33381813-2EE58305-319A-4600-AA26-C826F5F04B59Q33382570-8D38F8B6-73B7-4D65-899F-39F0F79F715CQ33382766-7295D064-9A7A-41B7-9E02-459CD776996AQ33386423-ECD53F9D-CAD9-4A9C-A412-CA50CBBAAEA1Q33387616-A61F391F-3873-42E6-A50C-6D7162D398B0Q33388071-A795852B-ABB3-4181-B092-FDAD8FA932F8Q33389392-E7823808-EC60-4ADB-8113-CBAEF7D6754DQ33389979-A0AB74EE-A707-4113-A86C-43661008EE78Q33393227-BF3E250C-47E8-4924-9610-C120C901B9A2Q33393270-13757E68-778C-48B6-9BC3-0BD8926EA571Q33393728-14DA3F5E-2D4E-4252-9052-385FD6BD6337Q33393992-897BFBDE-7DB7-40EA-B7B8-EA1E5DA7B18DQ33394819-16A73F75-4817-4AD7-9AB7-FEF0F89C41F8Q33395095-508A519C-E9B8-4A9E-B461-679E3E1A718BQ33395145-BEF173BD-A76F-4577-B12D-6C11BEBDE41CQ33395460-C0B757E6-A95A-4F69-AEFC-BEFF363CF589
P2860
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@ast
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@en
type
label
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@ast
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@en
prefLabel
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@ast
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@en
P2093
P2860
P1476
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
@en
P2093
Akira Okayama
Koichi Kokame
Toshiyuki Miyata
Yoshihiro Kokubo
P2860
P304
P356
10.1111/J.1365-2141.2005.05420.X
P407
P577
2005-04-01T00:00:00Z